XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating Costs and Expenses:        
General and administrative $ 1,265,000 $ 1,286,000 $ 2,685,000 $ 2,679,000
Research and development 1,932,000 1,603,000 3,049,000 3,238,000
Total Operating Costs and Expenses 3,197,000 2,889,000 5,734,000 5,917,000
Loss from Operations (3,197,000) (2,889,000) (5,734,000) (5,917,000)
Other Income :        
Interest income 2,000 6,000 2,000 44,000
Total Other Income 2,000 6,000 2,000 44,000
Net Loss (3,195,000) (2,883,000) (5,732,000) (5,873,000)
Net Loss Attributable to Non-controlling Interest 0 (16,000) (1,000) (42,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (3,195,000) (2,867,000) (5,731,000) (5,831,000)
Effect of Series A Preferred Stock Price adjustment     (7,402,000) 0
Net Loss Attributable to Common Stockholders $ 3,195,000 $ 3,322,000 $ 14,654,000 $ 6,752,000
Net Loss Per Share - Basic and Dilutive $ (0.02) $ (0.18) $ (0.13) $ (0.38)
Weighted average number of shares outstanding during the period - Basic and Dilutive 132,042,538 18,405,884 111,539,024 17,748,688
Series A Preferred Stock [Member]        
Other Income :        
Preferred Stock Dividends, Income Statement Impact $ 0 $ (63,000) $ (24,000) $ (125,000)
Effect of Series A Preferred Stock Price adjustment 0 0 7,402,000 0
Series B Preferred Stock [Member]        
Other Income :        
Net Loss Attributable to Non-controlling Interest   100,000 100,000 100,000
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0    
Preferred Stock Dividends, Income Statement Impact $ 0 $ (392,000) $ (1,497,000) $ (796,000)